Invokana Lawsuit

The dangers of Invokana®, also known as Canagliflozin, put those with Type 2 diabetes at risk for heart attacks, kidney damage and ketoacidosis. The following information is designed to better assist those suffering from the potential side effects of Invokana as well as how the Hollis Law Firm, an experienced Invokana law firm, can help with the litigation process.

Why are Invokana lawsuits being filed?

Invokana lawsuits are being filed because the makers of Invokana, Johnson & Johnson, did not warn patients about the potential fatal side effects. The U.S. Food and Drug Administration (FDA) has issued a drug safety communication that warns patients and physicians that sodium-glucose co-transporter 2 (SGLT2) inhibitors may lead to DKA – diabetic ketoacidosis. SGLT2 inhibitors are manufactured to help those patients suffering from Type 2 diabetes. They are designed to control blood sugar levels by helping the kidneys release glucose through urine, and preventing the body from reabsorbing glucose into the blood. The Invokana lawsuits state that if patients would have been warned about the potential heart attack, kidney failure and DKA, then the patient would have been either monitoring the potential side effects or would have been prescribed another medication to help them control their blood glucose levels.

FDA Invokana Safety Announcements

May 16, 2017: The FDA issued a warning that based on 2 large clinical trials (conducted AFTER Invokana was released), taking Invokana increases the risk of leg and foot amputations! The FDA advises patients to contact their health care professionals as soon as possible if they are experiencing any new pain, tenderness, sores, ulcers, or infections in their feet or legs. They clinical trials revealed that Invokana increased the risk of amputation by nearly two fold!

June 14, 2016: The FDA strengthened the existing warning about the risk of Acute Kidney Injury (AKI) for type 2 diabetics on Invokana. The FDA recommended that patients seek immediate medical attention if they experience decreased urine or swelling of in the legs or feet.

September 19, 2015: FDA strengthened the warning that Invokana increased the risk of bone fracturesThe and changes bone mineral density. The FDA noted that they would continue to evaluate the risk (use the US population as guinea pigs).

What are the Invokana side effects?

In May of 2015, the FDA has warned that Invokana can cause ketoacidosis, which is a condition in which the body produces a dangerous amount of ketones. High levels of ketones make the patient’s blood more acidic, and can poison the body. Symptoms of ketoacidosis include confusion, difficulty breathing, nausea, vomiting, unusual fatigue or sleepiness, and abdominal pain. Ketoacidosis can lead to severe dehydration, diabetic coma, or even death. In the 20 cases of Invokana-related ketoacidosis reported to the FDA, all 20 patients had to have treatments in a hospital. Most of the patients had only been taking Invokana for approximately two weeks.

Invokana side effect: Kidney Failure

Is a severe medical condition where the patient’s kidney begins to stop filtering waste products from the bloodstream. Filtration of the blood is extremely important because it maintains balances electrolytes, maintains blood pressure and blood glucose levels. If too many electrolytes are present in the bloodstream, it can cause serious illness such as confusion; lethargy; shortness of breath; abnormal heart rhythms; uncontrollable sweating; and death. The treatment for kidney failure is both expensive and painful. Treatments include kidney transplants or dialysis. If you or a loved one has experienced kidney failure after taking Invokana for a long period of time, you may have a viable case for compensation.

Invokana side effect: Heart Attack

A blockage in the bloodstream can be caused by any factor. When the blockage stops blood from the heart, it starves the heart of oxygen and other key nutrients. When the heart muscle becomes undernourished and causes permanent damage, it is referred to as a heart attack. During a heart attack, the patient’s heart dies and the chance of resuscitating them weakens with every millisecond. If you or a loved one has experienced a heart attack after taking Invokana for a long period of time, it is time to contact a trusted Invokana law firm today about your potential case.

Invokana side effect: Ketoacidosis (DKA)

DKA is a condition when the patient has extreme levels of ketones in their blood and if left untreated, will result in a diabetic coma. When a patient’s body does not get enough energy they need, the body starts to burn fat. Burning fat produces ketones to help breakdown the fat. High levels of ketones can quickly poison the body. If you or a loved one has experienced a diabetic coma or ketoacidosis after taking Invokana for a long period of time, contact an Invokana attorney today.

What are other SGLT2 inhibitors that are similar to the prescription drug Invokana?

Invokana by Johnson & Johnson has a wide array of SGLT2 inhibitors that are similar. The closest drug similar to Invokana is called Invokamet. These two drugs share the same active ingredient, canagliflozin. Below is a list of other SGLT2 inhibitors that are being investigated for potentially fatal side effects.

  • Jardiance
  • Xigduo XR
  • Glyxambi
  • Farxiga

Scientific Articles on Invokana

Jun 2017: Euglycemic Diabetic Ketoacidosis with Prolonged Glucosuria Associated with the Sodium-Glucose Cotransporter-2 Canagliflozin.

A case study on a 50-year-old women with type 2 diabetes who developed diabetic ketoacidosis (DKA) aftering starting canagliflozin (Invokana). The authors opined that SGLT2 inhibitors such as Invokana “may predispose patients not only to diabetic ketoacidosis but also prolonged glucosuria.” The studies authors also noted that “the US Food and Drug Administration issued a safety warning pertaining to the development of diabetic ketoacidosis (DKA) withthe use of SGLT2 inhibitors. DKA associated with SGLT2 inhibitors frequently develops in teh absence of hyperglycemia, which makes the diagnosis more challenging.”

May 2017: SGLT2 Inhibitor and Diabetic Ketoacidosis: Data From the FDA Adverse Event Reporting System.

The authors note that the US Food and Drug Administration Adverse Event Reporting System (FAERS) contains over 2,500 adverse event reports of suspected SGLT2i-induced diabetic ketoacidosis. 37 patients died from diabetic ketoacidosis while on a SGLT2i, such as Invokana.

Mar 2017: Diabetic Ketoacidosis with Mild Hyperglycemia Associated with the Use of Canagliflozin. Report of One Case with Type 1 Diabetes.

A case report on a 20 year old female with hypothyroidism and type 1 diabetes, who developed vomiting and abdominal pain 2 months after starting canagliflozin (Invokana). The patient’s blood pH was 7.1 (metabolic acidosis). The authors warn that “diabetic ketoacidosis with mild hyperglycemia is a major complications of sodium-glucose cotransporter 2 inhibitors.” (Invokana is a sodium-glucose cotransporter 2 inhibitor).

Feb 2017: SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.

A review of literature identified 34 case reports of SGLT2i-induced diabetic ketoacidosis. Symptoms included nausea, vomiting and abdominal pain. Invokana is a SGLT2i.

Aug 2016: Canagliflozin-Induced Diabetic Ketoacidosis: Case Report and Review of the Literature.

A case study of a 62-year-old women with type 2 diabetes and sudden-onset of diabetic ketoacidosis (DKA), due to canagliflozin (Invokana). She spent 5 day sin the intensive care unit. The authors note that at the time only 73 cases had been reported in the FDA’s adverse event reporting system.

Jun 2016: Euglycemic Diabetic Ketoacidosis in a 27 Year-Old Female Patient with Type-1 Diabetes Treated with Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor Canagliflozin.

A 27-year-old female with type 1 diabetes presented in diabetic ketoacidosis (DKA) after starting Invokana. The patient’s Invokana was discontinued and he did not go back into DKA.

Apr 2016: Diabetic Ketoacidosis with Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients with Type 1 Diabetes.

Invokana was associated with an increased incidence of serious adverse events of DKA in patients with type 1 diabetes inadequately controlled on insulin.

Mar 2016: Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern.

The authors warn that prompt association of diabetic ketoacidosis and Invokana is necessary to initiate appropriate therapy to stop the life threatening condition.

Invokana Lawsuit

Have you or a loved one suffered medical complications or injuries while taking Invokana (canagliflozin)? If the answer is yes, then you may be eligible for compensation. To find out if you or a loved can file an Invokana claim, speak to an experienced Invokana attorney today at the Hollis Law Firm. The attorneys at the Hollis Law Firm offer free case reviews for claims for Invokana and other dangerous drugs and devices. Each case is reviewed on an individual bases. The Hollis Law Firm represents clients from Kansas and Missouri, and partners with Invokana injury lawyers in all 50 states to provide representation to clients throughout the country. To speak to a member of the Hollis Law team about your case, please contact the Hollis Law Firm by completing a contact form or by calling (800) 701-3672